Teva Pharmaceuticals USA
Quick facts
Marketed products
- Activella®
- Augmentin® · Infectious Disease
Augmentin combines amoxicillin (a beta-lactam antibiotic) with clavulanic acid (a beta-lactamase inhibitor) to kill bacteria and overcome antibiotic resistance. - Azelastine hydrochloride and Fluticasone propionate
- Cefzil · Infectious Disease
- Cozaar® · Cardiovascular
Cozaar blocks angiotensin II receptors on blood vessels and tissues, causing vasodilation and reducing blood pressure. - FEMCON® Fe · Contraception / Women's Health
FEMCON Fe is an oral contraceptive that prevents pregnancy by suppressing ovulation through a combination of ethinyl estradiol and norethindrone, while the ferrous fumarate component replaces iron lost during menstruation. - Imitrex® · Neurology
Imitrex is a selective serotonin 5-HT1B/1D receptor agonist that constricts cranial blood vessels and inhibits neuropeptide release to relieve migraine headaches. - Imvexxy · Other
- Lamictal®
- Paxil®
- Trileptal® · Neurology
Oxcarbazepine blocks voltage-gated sodium channels in neuronal membranes, reducing repetitive neuronal firing and stabilizing hyperexcited neural tissue. - VTAMA® · Dermatology
VTAMA is a topical retinoid that binds to and activates retinoid X receptors (RXR) to promote skin cell differentiation and reduce inflammation in psoriasis. - YAZ® · Contraception / Gynecology
YAZ is an oral contraceptive that prevents ovulation through a combination of ethinyl estradiol (estrogen) and drospirenone (progestin), while drospirenone also provides antimineralocorticoid activity. - Zofran®
Phase 3 pipeline
- Tapinarof Cream 1% · Dermatology
Tapinarof is a topical aryl hydrocarbon receptor agonist that modulates the immune response and reduces inflammation. - Trifarotene 0.005 % Topical Cream · Dermatology
Trifarotene is a retinoic acid receptor gamma (RAR-gamma) agonist that modulates the expression of genes involved in cell differentiation and proliferation.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: